Insight Molecular Diagnostics Inc. (IMDX) — Congressional trading
Health Care · NASDAQ
iMDx develops decentralized molecular diagnostic kits for transplant organ rejection monitoring using donor-derived cell-free DNA biomarkers, enabling in-house testing at…
As of 2026-07-23, no U.S. House member has disclosed trading Insight Molecular Diagnostics Inc. (IMDX) in our data (STOCK Act Periodic Transaction Reports).
We match U.S. House Clerk STOCK-Act Periodic Transaction Reports to covered companies; a company can have no reported Congressional trades, or its disclosures may not yet be in our data. You can always check the primary source directly via the House Clerk link above, or see the full company profile.
More on Insight Molecular Diagnostics Inc.: company profile · insider trading · SEC filings · similar companies.
Source: U.S. House Clerk Periodic Transaction Reports (PTRs) filed under the STOCK Act. Disclosure can lag the actual trade by up to 45 days, so these are not real-time. Amounts are broad ranges as legally required — not exact figures. A transaction may belong to the member, their spouse, or a dependent child (see the owner column); a spouse or dependent trade is not the member's personal trade. This information is reused from the official public disclosure record for informational and public-interest (news) purposes only. Informational only — NOT financial advice, and NOT a signal to buy or sell.
Informational only — NOT financial advice. Congressional disclosures are sourced from the U.S. House Clerk public financial-disclosure archive.